{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:09:43Z","timestamp":1761844183758},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1097\/mou.0b013e3283555d04","type":"journal-article","created":{"date-parts":[[2012,7,19]],"date-time":"2012-07-19T13:15:35Z","timestamp":1342703735000},"page":"421-426","source":"Crossref","is-referenced-by-count":7,"title":["Monitoring high-risk bladder cancer"],"prefix":"10.1097","volume":"22","author":[{"given":"Christian","family":"Schwentner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnulf","family":"Stenzl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgios","family":"Gakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-13-20210206","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ejca.2005.08.032","article-title":"EORTC Genito-Urinary Cancer Group. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours.","volume":"42","author":"Sternberg","year":"2006","journal-title":"Eur J Cancer"},{"key":"R3-13-20210206","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00345-010-0635-2","article-title":"External validation and applicability of the EORTC risk tables for nonmuscle-invasive bladder cancer.","volume":"29","author":"Hernandez","year":"2011","journal-title":"World J Urol"},{"key":"R4-13-20210206","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1136\/jcp.2005.035394","article-title":"Multiprobe fluorescence in situ hybridisation: prognostic perspectives in superficial bladder cancer.","volume":"59","author":"Mian","year":"2006","journal-title":"J Clin Pathol"},{"key":"R5-13-20210206","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.eururo.2008.04.051","article-title":"European Association of Urology (EAU). EAU guidelines on nonmuscle-invasive urothelial carcinoma of the bladder.","volume":"54","author":"Babjuk","year":"2008","journal-title":"Eur Urol"},{"key":"R6-13-20210206","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/cncr.21712","article-title":"uCytImmunoCyt in the detection of recurrent urothelial carcinoma: an update on 1991 analyses.","volume":"108","author":"Mian","year":"2006","journal-title":"Cancer"},{"key":"R7-13-20210206","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/cncy.20168","article-title":"A multicolor fluorescence in situ hybridization assay: a monitoring tool in the surveillance of patients with a history of nonmuscle-invasive urothelial cell carcinoma: a prospective study.","volume":"119","author":"Galvan","year":"2011","journal-title":"Cancer Cytopathol"},{"key":"R8-13-20210206","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S1569-9056(11)60154-1","article-title":"Second-line application of urine-based molecular markers in transitional cell carcinoma diagnostics: a contribution to cost effectiveness.","volume":"10","author":"Schwentner","year":"2011","journal-title":"Eur Urol Suppl"},{"key":"R9-13-20210206","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1002\/ijc.24258","article-title":"The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guerin therapy.","volume":"124","author":"Savic","year":"2009","journal-title":"Int J Cancer"},{"key":"R11-13-20210206","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.eururo.2012.01.017","article-title":"Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study.","volume":"61","author":"Rink","year":"2012","journal-title":"Eur Urol"},{"key":"R12-13-20210206","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/j.1464-410X.2009.09130.x","article-title":"Prognostic significance of survivin-expressing circulating tumour cells in T1G3 bladder cancer.","volume":"106","author":"Gradilone","year":"2010","journal-title":"BJU Int"},{"key":"R13-13-20210206","first-page":"486","article-title":"Do patients benefit from routine follow-up to detect recurrences after radical cystectomy and ileal orthotopic bladder substitution Eur U","volume":"58","author":"Giannarini","year":"2010","journal-title":"rol"},{"key":"R14-13-20210206","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1200\/JCO.2005.05.3884","article-title":"Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer.","volume":"24","author":"International Bladder Cancer Nomogram Consortium","year":"2006","journal-title":"J Clin Oncol"},{"key":"R15-13-20210206","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.juro.2006.06.025","article-title":"Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder.","volume":"176","author":"Karakiewicz","year":"2006","journal-title":"J Urol"},{"key":"R16-13-20210206","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1464-410X.2009.09138.x","article-title":"Predicting individual outcomes after radical cystectomy: an external validation of current nomograms.","volume":"106","author":"Zaak","year":"2010","journal-title":"BJU Int"},{"key":"R19-13-20210206","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1470-2045(11)70333-3","article-title":"for the DOvE Study Group. Assessment of symptomatic women for early diagnosis of ovarian cancer: results from the prospective DOvE pilot project.","volume":"13","author":"Gilbert","year":"2012","journal-title":"Lancet Oncol"},{"key":"R20-13-20210206","first-page":"539","article-title":"Inflammation and cancer: back to Virchow L","volume":"357","author":"Balkwill","year":"2001","journal-title":"ancet"},{"key":"R21-13-20210206","first-page":"653","article-title":"C-reactive protein fifty years on L","volume":"1","author":"Pepys","year":"1998","journal-title":"ancet"},{"key":"R22-13-20210206","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1111\/j.1464-410X.2011.10234.x","article-title":"Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors: the TNR-C score.","volume":"108","author":"Gakis","year":"2011","journal-title":"BJU Int"},{"key":"R23-13-20210206","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/nrurol.2011.145","article-title":"C-reactive protein as a biomarker for urological cancers.","volume":"8","author":"Saito","year":"2011","journal-title":"Nat Rev Urol"},{"key":"R24-13-20210206","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1080\/07853890410026098","article-title":"Flt-1, angiopoietin-1 and P-selectin in breast and prostate cancer: further evidence for a role of platelets in tumour angiogenesis.","volume":"36","author":"Caine","year":"2004","journal-title":"Ann Med"},{"key":"R25-13-20210206","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/00000421-200304000-00007","article-title":"Levels of serum cytokines and acute phase proteins in patients with essential and cancer-related thrombocytosis.","volume":"26","author":"Alexandrakis","year":"2003","journal-title":"Am J Clin Oncol"},{"key":"R27-13-20210206","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/MOU.0b013e32834966fa","article-title":"The prognostic value of hematological and systemic inflammatory disorders in invasive bladder cancer.","volume":"21","author":"Gakis","year":"2011","journal-title":"Curr Opin Urol"},{"key":"R28-13-20210206","first-page":"2053","article-title":"Disseminated and circulating tumor cells for monitoring chemotherapy in urological tumors.","volume":"31","author":"Kruck","year":"2011","journal-title":"Anticancer Res"}],"container-title":["Current Opinion in Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOU.0b013e3283555d04","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T04:09:03Z","timestamp":1620965343000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00042307-201209000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/mou.0b013e3283555d04","relation":{},"ISSN":["0963-0643"],"issn-type":[{"value":"0963-0643","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}